Show simple item record

dc.contributor.authorAkalin, S
dc.contributor.authorIlkova, H
dc.contributor.authorYilmaz, MT
dc.contributor.authorErbas, T
dc.contributor.authorSatman, I
dc.contributor.authorBagriacik, N
dc.contributor.authorDamci, T
dc.contributor.authorKarsidag, K
dc.contributor.authorErsanli, Z
dc.date.accessioned2021-03-03T20:30:02Z
dc.date.available2021-03-03T20:30:02Z
dc.date.issued1997
dc.identifier.citationAkalin S., Erbas T., Yilmaz M., Ilkova H., Satman I., Ersanli Z., Karsidag K., Damci T., Bagriacik N., "Safety and efficacy of [Lys(B28),Pro(B29)]-human insulin in patients with diabetes mellitus", ISRAEL JOURNAL OF MEDICAL SCIENCES, cilt.33, sa.11, ss.716-719, 1997
dc.identifier.issn0021-2180
dc.identifier.otherav_5a3b0ea9-0ccd-4c4f-bf97-9bab6eaa42fc
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/63432
dc.description.abstractThe primary objectives of this study were to assess the efficacy and safety of Lys(B28), Pro(B29) in the treatment of patients with diabetes mellitus and to compare Lys(B28), Pro(B29) to currently available regular insulin with respect to quality of life. This study was designed as an open-label, non-comparative one. The number of patients enrolled in the trial was 39. At Visit 1 (week 0), blood samples for fasting, 1- and 2-hour postprandial blood glucose, and HbA1c were taken. At Visit 2 (week 6) and Visit 3 (week 12), fasting, 1- and 2-hour postprandial blood glucose, and HbAlc levels were measured again. There was no significant change in HbAlc, fasting blood glucose and 1- and 2-hour postprandial blood glucose levels. The 1- and 2-hour postprandial blood glucose excursions decreased significantly from Visit 1 to Visit 3. There were no serious adverse events during the study. Half of the patients had less hypoglycemia with LysPro insulin, while 25% had an increase in episodes. Thirty percent of patients were more satisfied with LysPro insulin than with the short-acting insulin that they had previously used. In conclusion, LysPro therapy can be regarded as safe, since there were no unexpected adverse events and no changes in the usual physical parameters.
dc.language.isoeng
dc.subjectKlinik Tıp (MED)
dc.subjectTIP, GENEL & İÇECEK
dc.subjectKlinik Tıp
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectTemel Tıp Bilimleri
dc.titleSafety and efficacy of [Lys(B28),Pro(B29)]-human insulin in patients with diabetes mellitus
dc.typeMakale
dc.relation.journalISRAEL JOURNAL OF MEDICAL SCIENCES
dc.contributor.department, ,
dc.identifier.volume33
dc.identifier.issue11
dc.identifier.startpage716
dc.identifier.endpage719
dc.contributor.firstauthorID119847


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record